Want to see KR:002720 full AI Analyst Report?

KUKJE PHARMA Co., Ltd. (002720) Price & Analysis

― Followers

002720 Stock Chart & Stats

₩3345.00

-₩55.00(-1.62%)

Oct 30, 2026

―

Day’s Range― - ―

52-Week Range₩2,810.00 - ₩5,470.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)3.89M

Market Cap

₩68.11B

Enterprise Value₩85.92B

Total Cash (Recent Filing)₩15.72B

Total Debt (Recent Filing)₩31.39B

Price to Earnings (P/E)13.9

Beta-0.08

Next Earnings

Nov 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.9%

Share Statistics

EPS (TTM)239.89

Shares Outstanding21,159,832

10 Day Avg. Volume1,687,495

30 Day Avg. Volume3,886,305

Financial Highlights & Ratios

PEG Ratio1.65

Price to Book (P/B)0.90

Price to Sales (P/S)0.50

P/FCF Ratio39.55

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong TTM Revenue ReboundThe sharp TTM revenue rebound indicates stronger recent commercial performance and expanding sales activity. Combined with a solid gross margin, this provides a foundation for maintaining product investment and supporting future earnings, although sustained execution will determine how durable the improvement becomes.

Improving Balance SheetLower debt relative to equity improves financial flexibility and reduces the burden that leverage can place on operating cash flow. The stronger balance-sheet position should give KUKJE PHARMA more capacity to manage business fluctuations and fund ongoing pharmaceutical activities over the next several quarters.

Positive TTM Cash GenerationPositive operating and free cash flow show that the company is generating cash from its business rather than relying entirely on external financing. This supports routine investment and financial resilience, even though the quality and consistency of cash conversion remain important constraints.

Bears Say

Thin And Compressed Profit MarginsThin and declining operating and net margins leave limited room to absorb cost increases or weaker demand without affecting earnings. The compression also suggests that recent revenue growth has not translated proportionately into profitability, which may limit durable earnings expansion.

Historical Earnings VolatilityA prior loss and periods of negative returns indicate that profitability can be sensitive to operating swings. This history reduces confidence that the recent rebound will translate into consistently strong earnings, making future performance more dependent on sustaining favorable business conditions.

Weak Cash-Flow ConversionLow conversion of reported earnings into free cash flow means accounting profitability is not fully reaching available cash resources. Sharply negative TTM free-cash-flow growth further points to greater reinvestment or working-capital demands, potentially increasing volatility in funding and capital allocation.

002720 FAQ

What was KUKJE PHARMA Co., Ltd.’s price range in the past 12 months?

KUKJE PHARMA Co., Ltd. lowest stock price was ₩2810.00 and its highest was ₩5470.00 in the past 12 months.

What is KUKJE PHARMA Co., Ltd.’s market cap?

KUKJE PHARMA Co., Ltd.’s market cap is ₩68.11B.

When is KUKJE PHARMA Co., Ltd.’s upcoming earnings report date?

KUKJE PHARMA Co., Ltd.’s upcoming earnings report date is Nov 12, 2026 which is in 11 days.

How were KUKJE PHARMA Co., Ltd.’s earnings last quarter?

KUKJE PHARMA Co., Ltd. released its earnings results on Aug 14, 2026. The company reported ₩78.932 earnings per share for the quarter.

Is KUKJE PHARMA Co., Ltd. overvalued?

According to Wall Street analysts KUKJE PHARMA Co., Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does KUKJE PHARMA Co., Ltd. pay dividends?

KUKJE PHARMA Co., Ltd. pays a Annually dividend of ₩30 which represents an annual dividend yield of 0.9%. See more information on KUKJE PHARMA Co., Ltd. dividends here

What is KUKJE PHARMA Co., Ltd.’s EPS estimate?

KUKJE PHARMA Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does KUKJE PHARMA Co., Ltd. have?

KUKJE PHARMA Co., Ltd. has 21,159,832 shares outstanding.

What happened to KUKJE PHARMA Co., Ltd.’s price movement after its last earnings report?

KUKJE PHARMA Co., Ltd. reported an EPS of ₩78.932 in its last earnings report. Following the earnings report the stock price went down -0.74%.

Which hedge fund is a major shareholder of KUKJE PHARMA Co., Ltd.?

Currently, no hedge funds are holding shares in KR:002720

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

KUKJE PHARMA Co., Ltd.

KUKJE PHARMA Co. Ltd. engages in the manufacture, sale, and distribution of pharmaceutical, cosmetics, and healthcare products. Its products include cephalosporins, penicillins, quinolones, aminoglycosides, macrolides, antibiotics, and antifungal and antiviral agents. The company was founded on July 27, 1959 and is headquartered in Seongnam, South Korea.